Taking Aim at HER3 in Lung Cancers Resistant to EGFR Inhibitors

In this podcast episode, Conor Ernst Steuer, MD, a medical oncologist; Frank Schneider, MD, a pathologist; and Elise Hitron, MSN, FNP-C, a phase I clinical trials nurse practitioner, engage in a multidisciplinary discussion of the latest management strategies for EGFR-mutated non-small-cell lung cancer, including the evolving treatment landscape for disease resistant to standard-of-care EGFR TKI inhibitors.

Elise Hitron, MSN, FNP-C Frank Schneider, MD Conor Ernst Steuer, MD Released: January 26, 2022